On September 15, 2023, Hemanext ONE was granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration.
- AABB Science Innovation Forum Nov 2023
- Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext’s Innovative Red Blood Cell (RBC) Processing and Storage System
- Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth
- Hemanext Announces Membership in European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
- Hemanext Announces a Strategic Partnership and Investment from Vitalant